Moleculera Biosciences, Inc. Company Profile

Background

Overview

Moleculera Biosciences, Inc., formerly known as Moleculera Labs, Inc., is a precision medicine company specializing in identifying immune-mediated causes of neurologic, psychiatric, and behavioral disorders. Founded in 2011, the company operates a fully accredited, high-complexity clinical laboratory in Oklahoma City, Oklahoma. Moleculera has developed the Autoimmune Brain Panel™, previously known as the Cunningham Panel™, which detects autoantibodies associated with various neuropsychiatric conditions.

Mission and Vision

Moleculera's mission is to advance precision medicine by uncovering the immune-mediated roots of chronic central nervous system (CNS) and cardiovascular disorders, as well as Alzheimer's disease. The company's vision is to transform medical practice for patients suffering from these conditions through innovative autoantibody testing and a robust biorepository of phenotypically curated specimens.

Primary Area of Focus

The company's primary focus is on diagnosing and treating immune-mediated neuropsychiatric disorders, including Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS), Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), and other conditions linked to autoimmune responses. Moleculera is also expanding into cardiovascular diseases, Long-COVID, and neurodegenerative disorders.

Industry Significance

Moleculera plays a pivotal role in the precision medicine landscape by providing diagnostic tools that enable clinicians to identify underlying autoimmune causes of neuropsychiatric symptoms, leading to more targeted and effective treatments. The company's innovative approach addresses a significant unmet need in the medical community, offering hope for patients who have not responded to traditional psychiatric treatments.

Key Strategic Focus

Core Objectives

• Diagnostic Innovation: Develop and commercialize diagnostic panels that identify autoantibodies associated with immune-mediated neuropsychiatric disorders.

• Expansion into New Markets: Extend product offerings to include panels for cardiovascular diseases, Long-COVID, and neurodegenerative disorders.

• Research and Development: Utilize a comprehensive biorepository to advance research into new biomarkers and predictive treatment algorithms.

Specific Areas of Specialization

• Autoimmune Neuropsychiatric Disorders: Focus on conditions such as PANDAS, PANS, and other autoimmune-related neuropsychiatric disorders.

• Cardiovascular Diseases: Develop diagnostic panels for autoimmune-related cardiovascular conditions.

• Long-COVID and Neurodegenerative Disorders: Create tests to identify immune-mediated mechanisms in Long-COVID and neurodegenerative diseases like Alzheimer's and Parkinson's.

Key Technologies Utilized

• Autoantibody Testing: Employ advanced immunoassays to detect specific autoantibodies linked to various disorders.

• Biorepository: Maintain a large collection of clinically annotated specimens to support research and development.

• Artificial Intelligence (AI): Collaborate with AI-focused companies to develop predictive treatment algorithms.

Primary Markets Targeted

• Healthcare Providers: Offer diagnostic services to clinicians across the United States and globally.

• Research Institutions: Provide tools for academic and clinical research into autoimmune-related conditions.

• Patients: Directly impact patient care by enabling accurate diagnoses and personalized treatment plans.

Financials and Funding

Funding History

• 2013: Raised $1.84 million in a financing round led by i2E, Inc., which invested $700,000 through its Oklahoma Seed Capital Fund.

• 2015: Received a two-year, $300,000 matching grant from the Oklahoma Center for the Advancement of Science and Technology (OCAST) to develop new diagnostic testing panels.

• 2024: Awarded a $500,000 matching OARS grant from OCAST to develop a predictive treatment algorithm integrated into its existing neuropsychiatric autoantibody panel.

Total Funds Raised

Approximately $2.14 million in equity funding and grants.

Notable Investors

• i2E, Inc.: Led the 2013 financing round through its Oklahoma Seed Capital Fund.

• OCAST: Provided grants in 2015 and 2024 to support the company's research and development efforts.

Intended Utilization of Capital

• Research and Development: Advance the development of new diagnostic panels and predictive treatment algorithms.

• Operational Expansion: Enhance laboratory capabilities and expand testing services.

• Strategic Partnerships: Collaborate with other organizations to broaden market reach and impact.

Pipeline Development

Key Pipeline Candidates

• Autoimmune Brain Panel™: A diagnostic test identifying autoantibodies associated with neuropsychiatric disorders.

• Autoimmune Heart Panel™: A forthcoming diagnostic panel targeting autoimmune-related cardiovascular diseases.

• Long-COVID Panel™: A planned test to detect immune-mediated mechanisms in patients with Long-COVID symptoms.

• Neurodegenerative Disorder Panel™: An anticipated panel for diagnosing and monitoring treatment in neurodegenerative diseases like Alzheimer's and Parkinson's.

Stages of Clinical Trials or Product Development

• Autoimmune Brain Panel™: Commercially available and utilized by over 2,500 clinicians worldwide.

• Autoimmune Heart Panel™: In development, with plans for clinical validation and commercialization.

• Long-COVID Panel™: In the research phase, aiming for development and clinical validation.

• Neurodegenerative Disorder Panel™: Early-stage development, with ongoing research to identify relevant biomarkers.

Target Conditions

• Autoimmune Brain Panel™: PANDAS, PANS, and other autoimmune-related neuropsychiatric disorders.

• Autoimmune Heart Panel™: Heart failure, cardiomyopathy, atrial fibrillation, and myocarditis.

• Long-COVID Panel™: Long-term symptoms following SARS-CoV-2 infection.

• Neurodegenerative Disorder Panel™: Alzheimer's disease, Parkinson's disease, and other dementias.

Relevant Timelines for Anticipated Milestones

• Autoimmune Brain Panel™: Ongoing clinical use with continuous data collection.

• Autoimmune Heart Panel™: Expected to enter clinical validation in the near future.

• Long-COVID Panel™: Anticipated development and clinical validation within the next few years.

• Neurodegenerative Disorder Panel™: Research phase, with potential for development in the coming years.

Technological Platform and Innovation

Proprietary Technologies

• Autoimmune Brain Panel™: A unique diagnostic test detecting autoantibodies associated with neuropsychiatric disorders.

• Biorepository: A collection of over 15,000 clinically annotated specimens supporting research and development.

Significant Scientific Methods

• Immunoassays: Advanced techniques to measure autoantibody levels in patient samples.

• Biomarker Discovery: Identification of novel biomarkers linked to autoimmune-mediated conditions.

• Predictive Algorithms: Development of AI-driven models to predict treatment outcomes based on patient data.

AI-Driven Capabilities

• Predictive Treatment Algorithms: Collaborations with AI-focused companies to develop models that assist clinicians in selecting effective treatments.

Leadership Team

Key Executive Profiles

• Dr. Craig Shimasaki, Ph.D., MBA: Co-Founder and CEO. Over 35 years of biotechnology experience, including leadership roles in multiple companies and successful FDA diagnostic approvals.

• Dr. Madeleine Cunningham, Ph.D.: Co-Founder and Chief Scientific Officer. A tenured professor at the University of Oklahoma with over 40 years of research in infection-induced autoimmune neuropsychiatric disorders.

• Rodney Cotton: Board Member. Former Senior Vice President at Roche Diagnostics with over 40 years in the life sciences field.